ERBB2 and breast carcinoma: In 2022, olaparib was approved by the FDA as an adjuvant treatment for patients with human epidermal growth factor receptor 2 (HER2)-negative and germline BRCA-mutated breast cancers following readout from the OlympiA trial [10].